Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DW6013 vs Linagliptin + Metformin in Healthy Adults
NCT05874167Phase 1Completed
- Sponsor
- Dongwha Pharmaceutical Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linagliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dongwha Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Time t up to 72 hours and Maximum Observed Plasma Concentration up to 72 hours. Started Aug 2022; status: completed.
02
Drugs
linagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05874167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05874167.